Epitalon 10 mg, 50 mg and Other Forms: Vials, Capsules, Tablets and Pens

Epitalon products are often offered online in quantities such as 10 mg, 50 mg, 100 mg or others, and may come in the form of vials, powder, capsules, tablets, sprays or ready-to-use pens. These designations describe the amount of material or product format, but do not define a clinically validated Epitalon dose, equivalent bioavailability or a standardised research protocol. [1–4]

Epitalon, also known as Epithalon or Epithalone, is the tetrapeptide Ala-Glu-Asp-Gly (AEDG). The unmodified peptide has a molecular weight of approximately 390.35 g/mol. The acetate and trifluoroacetate forms contain additional counterions, which is why their total molecular weights are different.

This distinction matters when interpreting queries such as Epitalon 10 mg, Epithalon 50 mg, Epitalon 100 mg, Epitalon capsules, Epitalon tablets or ready-to-use Epithalon pens. A higher number on the product label does not automatically mean greater potency per single administration, higher quality, better bioavailability, or greater similarity to the preparations used in published studies.

Most historical research on Epitalon used strictly defined experimental doses rather than modern commercial packaging sizes. In one recent in vitro study, 10 mg of Epitalon was used to prepare a laboratory stock solution, but the cultured cells were ultimately exposed to concentrations of only 0.1–1.0 μg/mL. [2] The 10 mg vial should therefore not be interpreted as an experimental dose or a human dose.

What does Epitalon 10 mg mean?

Epitalon 10 mg usually means the vial is labelled as containing a nominal total mass of 10 milligrams of Epitalon material. This does not imply 10 mg per dose, 10 mg/mL, or a clinically validated quantity, as the final concentration and experimental exposure depend on the formulation, volume, assay value, route of administration, and study protocol.

It is particularly important to distinguish between mass and concentration.

A vial labelled as 10 mg indicates the nominal amount of material in the container. It does not specify the concentration until the final volume of liquid is known.

It also does not confirm how much biologically active AEDG is actually present in the preparation, unless the product specification defines the chemical form and includes an appropriate content designation.

The 2025 study by Al-Dulaimi on human cells provides a good example. The researchers obtained 10 mg of Epitalon and used this quantity to prepare a stock solution with a concentration of 2.5 mg/mL. This solution was then serially diluted before being added to the cell cultures at final concentrations of 0.1, 0.2, 0.5 or 1.0 μg/mL. [2]

These values describe three different things:

10 mg was the initial mass used to prepare the stock solution.

2.5 mg/mL was the concentration of the stock solution.

0.1–1.0 µg/mL was the actual concentration applied to the experimental cells.

These values should not be treated as interchangeable.

The study does not establish 10 mg as a human dose or as a therapeutic cycle.

A discussion of the quantities used in research, rather than packaging designations, can be found in the article What Epithalon Dosages Have Been Reported in Research?

What is the Difference Between Epitalon 50 mg and a 10 mg Vial?

An Epitalon 50 mg vial nominally contains five times the total amount of peptide material compared to a 10 mg vial, but this difference alone does not provide information regarding purity, final concentration, experimental dosage, stability, bioavailability or biological efficacy. The package size should therefore be considered separately from the research protocol in which the peptide is used.

The numerical difference is simple: a container marked as 50 mg nominally contains five times more material than a container marked as 10 mg.

However, scientific interpretation requires more information.

The 50 mg vial may simply contain a larger amount of the same peptide, but researchers should still determine whether the product is:

• unmodified Epitalon or another analogue;
• free peptide, acetate or another salt form;
• correctly labelled in terms of peptide content;
• chemically pure;
• lyophilised or already dissolved;
• covered by batch-specific analytical documentation.

A larger vial does not automatically mean a more concentrated solution, because the final concentration depends on how the material is prepared for the experiment.

Nor does it mean that doses of 50 mg were used in the published research. Classical studies on rodents typically used quantities in the microgram range per animal, which is several orders of magnitude less than modern packaging designations such as 10, 50 or 100 mg. [1]

Therefore, the mass of the sales packaging and the experimental dose should remain separate concepts.

What Amounts of Epitalon Appear in Search Data?

The provided search cluster shows interest in Epitalon 10 mg, Epithalon 50 mg, and particularly Epitalon 100 mg. These queries reflect how users search for commercially available quantities of the product, rather than proof that any of them constitutes a standardised scientific or clinical dose.

Within the keyword cluster for this article, the phrase „epitalon 100mg” has the highest search volume among product quantity-related queries, whilst 10 mg and 50 mg also appear as frequent queries regarding pack sizes.

These numbers are best treated as units related to commercial packaging and user behaviour in search engines.

They should not be transformed into clinical claims, such as:

• 10 mg is the starting dose;
• 50 mg constitutes a complete cycle;
• 100 mg denotes a stronger therapeutic protocol;
• one vial size ensures greater efficacy than another.

Peer-reviewed literature regarding Epitalon does not confirm such relationships.

A useful distinction is as follows:

product quantity = quantity declared on the packaging,

whereas

experimental dose = the amount or concentration intentionally used in a specific experiment.

These concepts should remain clearly distinct.

What is an Epitalon Peptide Vial?

The vial containing the Epitalon peptide is simply a container holding material labelled as Epitalon, often in a dry or lyophilised form. The vial itself does not confirm the identity of the peptide, its purity, quantity, sterility, salt form, or stability. These properties require product specifications and appropriate analytical testing.

A vial is a packaging format, not a quality designation.

In peptide research, lyophilised materials are often supplied in vials because freeze-drying can facilitate storage and handling compared to keeping certain peptides continuously in aqueous solution. However, the actual advantage in terms of stability must be determined for the specific formulation.

In the case of Epitalon, individual analytical properties should be considered separately.

Identity determines whether the material is actually an AEDG.

The content label specifies how much Epitalon is in the preparation.

Purity indicates what proportion of the detected material corresponds to the target peptide compared to impurities or degradation products.

The salt or counterion form indicates whether the peptide exists as free Epitalon, acetate, TFA-bound material or another chemical form.

Sterility is a distinct microbiological property and cannot be inferred from the purity of HPLC.

Analytical confirmation is particularly important in the case of Epitalon, because Vanhee and colleagues used LC-MS/MS to analyse materials labelled as Epitalon and demonstrated that mass spectrometry methods can distinguish AEDG from a very similar peptide sequence. [3]

Therefore, a designation such as „Epitalon 10 mg vial” should be treated as a product specification declaration, which ideally should be analytically confirmed.

Information on storage and preparation of the solution can be found in the article Epitalon Reconstitution, Storage and Stability for Laboratory Research.

Do Epitalon Capsules and Tablets Have Scientific Confirmation?

Epitalon has been administered orally in rodent studies, but current evidence does not confirm that modern Epitalon capsules or tablets have validated bioavailability in humans, pharmacokinetics, clinical efficacy or equivalence to injectable forms. The mere availability of a capsule or tablet therefore does not mean that the formulation in question is based on confirmed clinical evidence.

There is actual research on oral Epitalon, but it should not be confused with the clinical validation of modern commercially available capsules or tablets.

In Khavinson-related research, Epithalon was administered orally to rats and biological effects in the gastrointestinal tract were observed. These results show that the oral route was investigated experimentally.

They do not, however, show what amount of intact AEDG reached the systemic circulation.

They also do not validate a specific capsule shell, tablet formulation, excipient composition, release profile, or contemporary manufacturing process.

A scientifically characterised oral formulation should ideally have evidence that the product releases chemically intact Epitalon, maintains adequate stability under gastrointestinal conditions, provides measurable systemic exposure where this is the target, and yields a reproducible pharmacokinetic profile.

In the analysed evidence, no robust human study comparing the bioavailability of Epitalon capsules and tablets has been established.

This matters because capsules and tablets are not automatically equivalent even in the case of conventional drugs with well-understood pharmacology. The formulation can affect the release rate and systemic exposure, and Epitalon currently lacks human pharmacokinetic data to allow for such comparisons.

A broader discussion can be found in the article Oral Epitalon and Sublingual Epitalon: Bioavailability and Evidence.

What is a Ready-to-Use Epithalon Pen?

A ready-to-use Epithalon pen would be a pre-filled device containing an Epitalon solution, designed to measure specific doses without the need for separate preparation. However, no significant peer-reviewed research base specific to Epitalon has been identified that confirms stability in the pen, delivery dose accuracy, pharmacokinetics, or clinical equivalence with historical studies regarding injections.

The term ready pen refers to a delivery device, and not to another Epitalon molecule.

In the case of approved medicines, such as insulin, pens contain prepared solutions or suspensions and utilise calibrated mechanical systems to deliver specified amounts.

Such a well-known device model cannot be automatically transferred to Epitalon.

A scientifically characterised Epitalon pen would require data concerning several distinct areas:

• identity and peptide content in solution;
• chemical stability during the stated storage period;
• microbiological quality;
• peptide compatibility with cartridge materials;
• accuracy of the delivered volume;
• dose homogeneity throughout the service life of the device;
• device reliability;
• route-specific pharmacokinetics and safety.

A targeted literature search of peer-reviewed literature regarding Epitalon revealed no Epitalon-specific controlled trial that validates a ready-to-use pen system.

Therefore, it should not be assumed that a pen sold as containing Epithalon is equivalent to subcutaneous solutions used in historical animal studies just because both involve injections.

Historical studies characterised peptide exposure, rather than the operation of modern pen devices.

What is the difference between Epitalon Acetate, Epitalon TFA and Lyophilised Powder?

Epitalon acetate and Epitalon TFA contain the same AEDG peptide sequence associated with different counterions, whereas „lyophilised powder” describes the physical state of the formulation rather than its chemical salt form. These differences may affect molecular weight, analytical calculations, formulation properties, stability and the interpretation of the declared peptide content. [1,4–6]

These terms describe different material properties.

Unmodified Epitalon

PubChem identifies Epitalon as H-Ala-Glu-Asp-Gly-OH with the molecular formula C14H22N4O9 and a molecular weight of approximately 390.35 g/mol.

A 2025 review describes the free form of Epitalon as the form most frequently discussed in historical literature. [1]

Epitalon Acetate

Epitalon acetate contains AEDG bound to acetic acid or acetate as a counterion.

PubChem lists Epitalon acetate as H-Ala-Glu-Asp-Gly-OH·CH3CO2H with a molecular weight of approximately 450.40 g/mol.

In July 2026, the FDA Pharmacy Compounding Advisory Committee also analysed free Epitalon and Epitalon acetate as related yet distinct active ingredients for compounding.

Their separate consideration shows why the exact chemical form should be documented.

Epitalon TFA

TFA stands for trifluoroacetate, a counter-ion frequently encountered during the purification of synthetic peptides.

PubChem contains a separate entry for Epithalon trifluoroacetate, with a molecular weight of approximately 504.37 g/mol for the registered structure associated with TFA.

A 2025 review of Epitalon also documents the use of Epitalon trifluoroacetate in at least one published experiment. [1]

General research into peptide manufacturing explains why this distinction matters. TFA can remain bound to synthetic peptides after the purification process, and pharmaceutical product development may involve exchanging the counterion from TFA to acetate. [4,5]

However, this does not mean that one Epitalon salt is clinically better than the other.

Lyophilised Epitalon

The term freeze-dried describes the physical state of a product after the sublimation drying process.

The lyophilised vial may contain free Epitalon, Epitalon acetate, TFA-related material or another validated formulation.

Therefore:

acetate/TFA = chemical counterion information,

whereas

lyophilised = information about the physical form of the formulation.

These are different product features.

Does the Counterion Change the Amount of AEDG in the 10 mg or 50 mg Product?

Potentially so. If the declared mass includes all of the peptide salt rather than the equivalent content of the peptide itself, the acetate or TFA increases the total molecular mass. Equal milligram amounts of different salt forms therefore do not necessarily correspond to the same number of moles of AEDG, unless the method of determining content and the counterion specification have been clearly defined.

This is an important analytical distinction.

Unmodified Epitalon has a molecular mass of approximately 390.35 g/mol.

PubChem lists Epitalon acetate at around 450.40 g/mol, and Epithalon TFA at around 504.37 g/mol for the respective registered forms.

Because counterions increase mass, equal milligram amounts of different chemical forms are not necessarily molar equivalents.

However, manufacturers can declare the content in various ways. For example, a product may state the peptide equivalent instead of the total salt mass.

Researchers should therefore check the definition of the content designation rather than drawing conclusions solely from the front label.

The specification or certificate should ideally state whether the given mass means:

• the total mass of the material;
• free peptide equivalent;
• peptide along with counterion;
• AEDG content adjusted based on the assay.

Without such data, a precise comparison of the 10 mg acetate product with the 10 mg TFA product can be misleading.

What Packaging Information is Important in Laboratory Testing?

In laboratory research, useful Epitalon packaging should specify the peptide, nominal amount, assay or purity, sequence, salt or counterion form, batch number, storage requirements, expiry or retest date, and relevant analyses. Vial size alone or the quantity in milligrams is not enough to assess the suitability of the material for research.

The investigative packaging should enable the unequivocal association of the physical material with the analytical documentation.

Relevant information may include:

• product name and peptide sequence;
• nominal mass, e.g. 10 mg, 50 mg or 100 mg;
• batch number;
• chemical form, e.g. free peptide, acetate or TFA;
• method for determining peptide content;
• chromatographic purity;
• identity verification;
• lyophilised product or solution;
• storage conditions;
• expiry date or re-test date;
• information on residual solvents or counterions, if relevant;
• sterility and endotoxin data, when required by the experiment;
• manufacturer's or laboratory documentation confirming these parameters.

Analytical testing is important because purity and identity are not the same thing.

A chromatogram may indicate that the sample is relatively homogeneous, whereas mass spectrometry or another independent analytical method can help determine whether the dominant material is indeed AEDG.

The 2015 Vanhee study demonstrates this difference. The researchers used LC-MS/MS to identify Epitalon in the analysed preparations, specifically considering the possibility of confusion with a closely related peptide sequence. [3]

A 2025 review of Epitalon also indicates that acetate and TFA forms occur in a broader chemical and commercial environment. [1]

For this reason, the designation „Epitalon 100 mg” is incomplete scientific information if the material itself has not been adequately characterised.

How to Compare Epitalon 10 mg, 50 mg and 100 mg Products?

The quantity in the pack is just one of the variables.

The basic principle is that the amount in milligrams, product form, chemical form and route of administration are separate variables.

Frequently Asked Questions about Epitalon Product Forms

What does Epitalon 100 mg mean?

Epitalon 100 mg usually refers to a product labelled as containing a nominal total mass of 100 milligrams. This does not mean that 100 mg is an evidence-based dose or a complete research cycle.

Published animal studies have often used quantities at the microgram level, and modern cell experiments have used much lower final concentrations.

Is Epitalon 50 mg stronger than Epitalon 10 mg?

Nominally, the 50 mg container contains more total material than the 10 mg container, but describing it as „stronger” can be misleading.

Concentration, experimental dose, purity, chemical form, formulation and route of administration are distinct variables. A larger vial does not confirm greater biological activity or clinical efficacy.

Was the 10 mg Epitalon vial used in research?

Yes. In the 2025 human cell study, 10 mg of Epitalon was used initially to prepare the laboratory stock solution, but the cultured cells were ultimately exposed to only 0.1–1.0 μg/mL. [2]

Therefore, the initial amount of 10 mg should not be interpreted as a human dose.

Are Epitalon Capsules Clinically Validated?

There is currently no robust evidence confirming the clinical efficacy or absolute bioavailability of generic Epitalon capsules in humans.

Oral Epithalon was studied in rats, but these experiments do not confirm modern capsule formulations or their equivalence to injection administration.

Are Epitalon Tablets Evidence-Based?

There is no strong clinical evidence showing that Epitalon tablets provide predictable systemic exposure or confirmed therapeutic effects in humans.

The existence of the tablet and the chemical identity of the peptide are issues distinct from bioavailability and clinical efficacy.

Is Epitalon peptide scientifically validated?

No significant, peer-reviewed database of research specific to Epitalon confirming ready-to-use pens has been identified.

A pen-type system would require separate evaluation of formulation stability, delivered dose accuracy, device performance, pharmacokinetics, and route-specific safety before equivalence to other Epitalon preparations could be claimed.

Is Epitalon Acetate the Same as Epitalon?

Epitalon acetate contains the same AEDG sequence with acetate as a counterion, but is a distinct chemical form with a different total molecular mass.

PubChem records Epitalon and Epitalon acetate separately, and the FDA analysed the free and acetate forms separately during its 2026 compounding review.

What is Epitalon TFA?

Epitalon TFA is Epitalon bound with trifluoroacetate.

TFA is commonly encountered during the production and purification of synthetic peptides, and PubChem contains Epithalon trifluoroacetate as a separate chemical entry.

His presence should be documented, as the counterion mass and formulation properties can influence the analytical interpretation.

Does „Liofilizowany” mean „Acetate”?

No.

Lyophilisation denotes the freeze-drying process, whilst acetate defines the chemical counterion.

The lyophilised preparation may contain free Epitalon, acetate, TFA or another formulation, depending on the manufacturing method.

Product Form Evidence Restrictions

One of the main limitations is that commercial packaging terminology has evolved much faster than the clinical evidence supporting these product forms.

Search results may include 10 mg, 50 mg and 100 mg products, but these pack sizes were not established in dose-ranging clinical trials as standardised quantities of Epitalon.

Similarly, capsules, tablets, nasal sprays and pens may be commercially available even when there is a lack of appropriate human pharmacokinetic validation.

Another limitation is incomplete reporting of the chemical form. The same AEDG sequence can be delivered with different counter-ions. A 2025 review lists acetate and TFA among the forms encountered in the wider literature concerning Epitalon, whereas the FDA in its 2026 review on compounding analysed free Epitalon and Epitalon acetate separately. [1]

An additional limitation is the fact that freeze-drying does not establish the shelf life. The stability of a specific product requires appropriate analytical testing throughout the declared storage period.

The mass of the packaging may also not always be treated as equivalent to the peptide content corrected on the basis of the assay, if the salt form, amount of counterion, water content or other formulation ingredients are not specified.

Finally, there is no scientific basis for assuming that a 10 mg vial, a 100 mg vial, a capsule, a tablet, a spray or a pre-filled pen provide equivalent biological exposure just because each of these products is labelled as Epitalon.

Disclaimer

This article is for educational and informational purposes regarding laboratory research only. It should not be interpreted as medical advice, dosing guidelines, injection instructions, product selection recommendations, or a recommendation for the use of Epitalon.

Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) remains an experimental peptide, and commercial quantities such as 10 mg, 50 mg or 100 mg do not constitute established clinical doses. It should not be assumed that capsules, tablets, ready-to-use pens, lyophilised vials, acetate preparations and TFA-related preparations provide equivalent exposure, quality, stability or biological effects.

Researchers should rely on the specific batch analytical specification, validated laboratory procedures, and relevant institutional and regulatory requirements when evaluating Epitalon materials. Further pharmacokinetic, formulation, stability, and human clinical studies are necessary before standardised comparisons between these product forms can be established.

References

[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691

[2] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x

[3] Vanhee, C., Moens, G., Van Hoeck, E., Deconinck, E., & De Beer, J. O. (2015). Identification of the small research tetrapeptide Epitalon, assumed to be a potential treatment for cancer, old age and retinitis pigmentosa in two illegal pharmaceutical preparations. Drug Testing and Analysis, 7(3), 259–264. https://doi.org/10.1002/dta.1771

[4] Khondee, S., Wang, S. H., Kumar, R., & Dhawan, S. (2019). Formulation composition and process affect counterion for CSP7 peptide. AAPS PharmSciTech, 20. https://pubmed.ncbi.nlm.nih.gov/31569515/

[5] Araz, O., Chao, C.-M., Mo, C., et al. (2020). Oral delivery of a tetrameric tripeptide inhibitor of VEGFR1 suppresses pathological choroid neovascularisation. International Journal of Molecular Sciences, 21(3), 899. https://doi.org/10.3390/ijms21030899

[6] National Center for Biotechnology Information. PubChem Compound Summary: Epitalon, CID 219042.

[7] National Center for Biotechnology Information. PubChem Compound Summary: Epitalon acetate, CID 146155988.

[8] National Center for Biotechnology Information. PubChem Compound Summary: Epithalon trifluoroacetate, CID 155977637.

[9] U.S. Food and Drug Administration. (2026). July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee: Epitalon-related bulk drug substances (Epitalon free base and Epitalon acetate).